A 28-year-old man with a history of recurrent Neisseria meningitidis meningitis (2 episodes in 18 months) presents for evaluation. Serum complement levels are normal. Serum immunoglobulin levels are normal. Flow cytometry shows normal B and T cell counts. Specific antibody response to meningococcal polysaccharide vaccine is absent. What is the most appropriate immediate next step in management?

Explanation

## Clinical Diagnosis This patient presents with **Asplenia or Functional Asplenia** (or **Complement Deficiency with Normal Levels** — but the clinical picture suggests **specific antibody deficiency to polysaccharide antigens**). **Key Point:** The recurrent meningococcal infections + **absent antibody response to polysaccharide vaccine** despite normal immunoglobulin levels indicates a **defect in antibody production to T cell-independent (polysaccharide) antigens**. This is characteristic of: 1. **Asplenia** (surgical or functional) 2. **Specific polysaccharide antibody deficiency (SPAD)** 3. **IgG subclass deficiency** (especially IgG2, which responds to polysaccharides) ## Antibody Response to Polysaccharide Antigens ### T Cell-Independent vs. T Cell-Dependent Antigens | Feature | Polysaccharide (T-independent) | Protein (T-dependent) | |---------|--------------------------------|----------------------| | **B cell activation** | Direct, no T cell help | Requires T cell help | | **Antibody class** | Primarily IgM, IgG2 | IgG1, IgG3, IgA | | **Germinal center** | Minimal | Robust | | **Affinity maturation** | Absent/minimal | Yes | | **Memory response** | Weak | Strong | | **Spleen dependence** | **High** | Moderate | **High-Yield:** The **spleen is critical for antibody responses to polysaccharides** because: - Marginal zone B cells (in spleen) specialize in polysaccharide responses - Splenic macrophages clear opsonized bacteria - Without spleen → recurrent encapsulated organism infections (Neisseria, Streptococcus pneumoniae, Haemophilus influenzae) ## Management Algorithm ```mermaid flowchart TD A["Recurrent meningococcal infections<br/>Absent response to polysaccharide vaccine"]:::outcome --> B{"Asplenia or<br/>polysaccharide Ab deficiency?"}:::decision B -->|Confirmed| C["Initiate prophylactic penicillin<br/>Long-term"]:::action C --> D["Give meningococcal conjugate vaccine<br/>MenACWY"]:::action D --> E["Measure post-vaccination<br/>antibody titers at 4 weeks"]:::action E --> F{"Adequate response?"}:::decision F -->|Yes| G["Continue penicillin prophylaxis"]:::outcome F -->|No| H["Consider IgG2 subclass deficiency<br/>or SPAD"]:::outcome ``` ## Immediate Next Step: Dual Approach ### 1. **Prophylactic Penicillin (Immediate)** **Key Point:** Prophylactic antibiotics are **mandatory** in patients with recurrent meningococcal disease because: - Prevent bacteremia and meningitis - Dosing: Penicillin V 250 mg PO BID or Penicillin G IM monthly - Duration: **Long-term** (often lifelong if asplenic) - Patient education: Seek immediate care for fever ### 2. **Meningococcal Conjugate Vaccine (MenACWY)** **Clinical Pearl:** Conjugate vaccines (MenACWY) are **superior to polysaccharide vaccines** (MenPS) in asplenic/hyposplenism patients because: - **Conjugate = polysaccharide linked to protein carrier** - Converts T cell-independent antigen → **T cell-dependent** - Stimulates germinal center response and memory B cells - Provides **durable immunity** - Polysaccharide vaccines alone fail in asplenia (as seen in this case) ### 3. **Post-Vaccination Antibody Assessment** **High-Yield:** Measure serum meningococcal-specific IgG antibodies **4 weeks post-vaccination** to: - Confirm adequate response - Identify persistent polysaccharide antibody deficiency (SPAD) if response is still absent - Guide further management (repeat vaccination, IVIG, or eculizumab if complement deficiency is later confirmed) ## Why Other Options Are Incorrect | Option | Why Wrong | |--------|----------| | **Penicillin + splenectomy evaluation only** | Splenectomy is **not indicated** for recurrent meningococcal disease in an immunocompetent patient. Splenectomy is reserved for hereditary spherocytosis, ITP, or other splenic pathology. This patient needs vaccination + prophylaxis, not organ removal. | | **Conjugate vaccine + 4-week titers only** | Omits **prophylactic penicillin**, which is essential to prevent infection *while* awaiting vaccine response. Vaccination alone is insufficient; dual approach (prophylaxis + vaccine) is standard. | | **Genetic testing + eculizumab empirically** | Complement levels are **normal**, making complement deficiency unlikely. Eculizumab (C5 inhibitor) is indicated only if complement deficiency is confirmed. Empiric eculizumab is expensive, unnecessary, and delays proven therapies. Genetic testing is a secondary step if vaccine response remains absent. | ## Long-Term Management **Key Point:** Asplenic or SPAD patients require: 1. **Prophylactic penicillin** (lifelong) 2. **Conjugate meningococcal vaccine** (MenACWY) + booster every 5 years 3. **Pneumococcal vaccine** (PCV20 or PCV15 + PPSV23) 4. **Haemophilus influenzae type b vaccine** 5. **Patient alert card** (asplenic/immunocompromised) 6. **Immediate antibiotics** for fever (empiric coverage for encapsulated organisms) [cite:Harrison 21e Ch 372; Robbins 10e Ch 6]